School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland.
Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland.
Expert Opin Biol Ther. 2022 Jul;22(7):929-944. doi: 10.1080/14712598.2022.2095901. Epub 2022 Jul 11.
The role of the gut microbiota in health and the pathogenesis of several diseases has been highlighted in recent years. Even though the precise mechanisms involving the microbiome in these ailments are still unclear, microbiota-modulating therapies have been developed. Fecal microbiota transplantation (FMT) has shown significant results against infection (CDI), and its potential has been investigated for other diseases. Unfortunately, the technical aspects of the treatment make it difficult to implement. Pharmaceutical technology approaches to encapsulate microorganisms could play an important role in providing this treatment and render the treatment modalities easier to handle.
After an overview of CDI, this narrative review aims to discuss the current formulations for FMT and specifically addresses the technical aspects of the treatment. This review also distinguishes itself by focusing on the hurdles and emphasizing the possible improvements using pharmaceutical technologies.
FMT is an efficient treatment for recurrent CDI. However, its standardization is overlooked. The approach of industrial and hospital preparations of FMT are different, but both show promise in their respective methodologies. Novel FMT formulations could enable further research on dysbiotic diseases in the future.
近年来，人们越来越关注肠道微生物群在健康和多种疾病发病机制中的作用。尽管涉及微生物组在这些疾病中的确切机制尚不清楚，但已经开发出了调节微生物组的疗法。粪便微生物群移植（FMT）已显示出对 感染（CDI）的显著效果，并且已经针对其他疾病对其潜在效果进行了研究。不幸的是，该治疗的技术方面使得难以实施。封装微生物的制药技术方法在提供这种治疗方法和使治疗方式更容易处理方面可能发挥重要作用。
在概述 CDI 之后，本叙述性综述旨在讨论 FMT 的当前配方，并特别针对治疗的技术方面进行讨论。这篇综述的另一个特点是重点关注障碍，并强调使用制药技术进行可能的改进。
FMT 是治疗复发性 CDI 的有效方法。然而，其标准化被忽视了。工业和医院制备 FMT 的方法不同，但两者都在各自的方法中显示出了前景。新型 FMT 配方可能为未来的肠道菌群失调疾病研究提供更多可能。
